Effects of levodopa on regional cerebral metabolism and blood flow

Movement Disorders

Volumn 30, Issue 1, 2015, Pages 54-63

  Ko, Ji Hyun ^a,b   Lerner, Renata P ^a   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Blood flow; Dopamine; Levodopa; Metabolism; Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LEVODOPA; ANTIPARKINSON AGENT;

BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN REGION; COGNITION; DOPAMINERGIC ACTIVITY; FUNCTIONAL NEUROIMAGING; HUMAN; LONG TERM CARE; METABOLIC ACTIVATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD FLOW; BRAIN CORTEX; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; METABOLISM; NEUROIMAGING; VASCULARIZATION;

ANIMALS; ANTIPARKINSON AGENTS; CEREBRAL CORTEX; COGNITION DISORDERS; HUMANS; LEVODOPA; NEUROIMAGING; PARKINSON DISEASE; REGIONAL BLOOD FLOW;

EID: 84920848459     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26041     Document Type: Review

References (66)

1. Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain 2006;129:2667-2678.
2. Herz DM, Siebner HR, Hulme OJ, Florin E, Christensen MS, Timmermann L. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease. Neuroimage 2014;90:15-23.
3. Jubault T, Monetta L, Strafella AP, Lafontaine AL, Monchi O. L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network. PLoS One 2009;4:e6154.
4. Ng B, Palmer S, Abugharbieh R, McKeown MJ. Focusing effects of L-dopa in Parkinson's disease. Hum Brain Mapp 2010;31:88-97.
5. Palmer SJ, Eigenraam L, Hoque T, McCaig RG, Troiano A, McKeown MJ. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease. Neuroscience 2009;158:693-704.
6. Hornykiewicz O. [Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man]. Deutsch Med Wochenschr 1962;87:1807-1810.
7. O'Reilly S, Loncin M, Cooksey B. Dopamine and basal ganglia disorders. Neurology 1965;15:980-984.
8. Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Ann Neurol 1984;15:419-424.
9. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
10. Herman T, Giladi N, Hausdorff JM. Neuroimaging as a window into gait disturbances and freezing of gait in patients with Parkinson's disease. Curr Neurol Neurosci Rep 2013;13:411.
11. Herz DM, Florin E, Christensen MS, et al. Dopamine replacement modulates oscillatory coupling between premotor and motor cortical areas in Parkinson's disease. Cereb Cortex 2013: Epub ahead of print.
12. Sabatini U, Boulanouar K, Fabre N, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000;123:394-403.
13. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009;32:548-557.
14. Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol 2012;72:635-647.
15. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007;130:1834-1846.
16. Holtbernd F, Gagnon JF, Postuma RB, et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 2014;82:620-627.
17. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010;30:1049-1056.
18. Wu P, Wang J, Peng S, et al. Metabolic brain network in the Chinese patients with Parkinson's disease based on 18F-FDG PET imaging. Parkinsonism Relat Disord 2013;19:622-627.
19. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007;64:20-24.
20. Lin TP, Carbon M, Tang C, et al. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 2008;131:1373-1380.
21. Ma Y, Peng S, Spetsieris PG, Sossi V, Eidelberg D, Doudet DJ. Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J Cereb Blood Flow Metab 2012;32:633-642.
22. Pifl C, Schingnitz G, Hornykiewicz O. Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991;44:591-605.
23. Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchison WD, Lozano AM. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 2001;86:249-260.
24. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 2001;16:1014-1022.
25. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001;57:2083-2088.
26. Buhmann C, Glauche V, Sturenburg HJ, Oechsner M, Weiller C, Buchel C. Pharmacologically modulated fMRI: cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain 2003;126:451-461.
27. Haslinger B, Erhard P, Kampfe N, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001;124:558-570.
28. Ko JH, Mure H, Tang CC, et al. Parkinson's disease: increased motor network activity in the absence of movement. J Neurosci 2013;33:4540-4549.
29. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007;34:714-723.
30. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70:1470-1477.
31. Mattis PJ, Tang CC, Ma Y, Dhawan V, Eidelberg D. Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology 2011;77:858-865.
32. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
33. Niethammer M, Tang CC, Ma Y, et al. Parkinson's disease cognitive network correlates with caudate dopamine. Neuroimage 2013;78:204-209.
34. Cools R, D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 2011;69:e113-e125.
35. Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:1204-1210.
36. Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol Aging 2012;33:e229-e239.
37. Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009;73:1670-1676.
38. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-1748.
39. Ray NJ, Strafella AP. The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. Mov Disord 2012;27:1484-1492.
40. Wang J, Ma Y, Huang Z, Sun B, Guan Y, Zuo C. Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease. J Neurol 2010;257:72-78.
41. Trost M, Su S, Su P, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 2006;31:301-307.
42. Feigin A, Kaplitt MG, Tang C, et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 2007;104:19559-19564.
43. Hirano S, Asanuma K, Ma Y, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci 2008;28:4201-4209.
44. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007;27:597-605.
45. Ma Y, Huang C, Dyke J, et al. Parkinson's disease spatial covariance pattern: non-invasive quantification with perfusion MRI. J Cereb Blood Flow Metab 2010;30:505-509.
46. Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. Neuroimage 2012;61:228-239.
47. Lerner RP, Bimpisidis Z, Dewey S, et al. Dissociation between metabolic and neurovascular responses to levodopa treatment in a rat model of Parkinson's disease [abstract]. Mov Disord 2014;29(Suppl 1):216.
48. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 2007;10:1369-1376.
49. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178-201.
50. Paulson OB, Hasselbalch SG, Rostrup E, Knudsen GM, Pelligrino D. Cerebral blood flow response to functional activation. J Cereb Blood Flow Metab 2010;30:2-14.
51. Ohlin KE, Francardo V, Lindgren HS, et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 2011;134:2339-2357.
52. Westin JE, Lindgren HS, Gardi J, et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3, 4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 2006;26:9448-9461.
53. Lindgren HS, Ohlin KE, Cenci MA. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 2009;34:2477-2488.
54. Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 2006;99:381-392.
55. Pita Lobo P, Coelho M, Mestre TA, Rosa MM, Ferreira JJ. Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism. Mov Disord 2013;28:1212-1214.
56. Hong JY, Oh JS, Lee I, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology 2014;82:1597-1604.
57. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 2010;112:1465-1476.
58. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
59. Krimer LS, Muly EC 3rd, Williams GV, Goldman-Rakic PS. Dopaminergic regulation of cerebral cortical microcirculation. Nat Neurosci 1998;1:286-289.
60. Iadecola C. Neurogenic control of the cerebral microcirculation: is dopamine minding the store? Nat Neurosci 1998;1:263-265.
61. Astradsson A, Jenkins BG, Choi JK, et al. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates: evidence from in vivo neuroimaging studies. Neurobiol Dis 2009;35:348-351.
62. Herz DM, Haagensen BN, Christensen MS, et al. The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Ann Neurol 2014;75:829-836.
63. Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt MG, Eidelberg D. Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. J Neurosurg 2009;110:1278-1282.
64. Mure H, Hirano S, Tang CC, et al. Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage 2011;54:1244-1253.
65. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991;59:12-19.
66. Maassen GH. The standard error in the Jacobson and Truax Reliable Change Index: the classical approach to the assessment of reliable change. J Int Neuropsychol Soc 2004;10:888-893.